Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Grantham Mayo Van Otterloo & Co. LLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 11.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 967,975 shares of the biopharmaceutical company’s stock after purchasing an additional 97,671 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Bristol Myers Squibb were worth $43,656,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Norges Bank bought a new stake in Bristol Myers Squibb during the second quarter worth about $1,554,154,000. Charles Schwab Investment Management Inc. grew its position in Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after purchasing an additional 9,171,098 shares in the last quarter. Man Group plc raised its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after purchasing an additional 4,961,869 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BMY shares. Leerink Partners lifted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Citigroup increased their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Guggenheim restated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.00.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $60.21 on Friday. The firm’s 50 day moving average price is $57.66 and its two-hundred day moving average price is $51.01. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The stock has a market cap of $122.62 billion, a PE ratio of 17.45, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the firm posted $1.67 EPS. The business’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.